Refine by
Nervous System Articles & Analysis
216 news found
Summary Did you know that between 64% and 93% of dentists and dental hygienists experience work-related musculoskeletal pain?1 The solution to working pain-free might lie in better ergonomics education. Ergonomics is vital in dentistry, where professionals often work in static, awkward positions that can lead to musculoskeletal disorders and chronic pain. Proper ergonomic practices can help ...
In the field of food science, liposomes have attracted much attention as delivery systems. Compared to other vesicles, liposomes have unique advantages in encapsulating functional food substances. ...
Ultrasound has long been used for real-time imaging inside the human body, except the Central Nervous System (CNS), because ultrasound cannot penetrate bone. Traditionally, the only way to image inside the cranial compartment was through Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI), which can be time-consuming and may require sedation. ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. ...
About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a ...
” About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization ...
CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") ...
About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a ...
The hustle and bustle of the modern workplace often leaves us longing for new ways to kickstart our day with energy and focus. At the LDARtools office, a refreshing cold plunge has been the top choice. In the pursuit of workplace wellness, a morning ice bath has been an unexpected yet highly effective solution in jumpstarting the day. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth ...
” About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization ...
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple ...
Bayer will also report new data looking at larotrectinib, a highly selective and central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor, approved for the treatment of patients with TRK fusion solid tumors, exploring the concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) ...
ByBayer AG
This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial6 and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.7 The product is approved under the brand name Nubeqa™ in more than 80 countries ...
ByBayer AG
This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.4 Nubeqa is approved in more than 80 countries around the world for the treatment of ...
ByBayer AG
This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.8 The product is approved in more than 80 countries around the world, including the U.S., ...
ByBayer AG
This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial4 and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.5 The product is approved under the brand name Nubeqa™ in more than 80 countries ...
ByBayer AG
This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial9 and the improved verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.10 The product is approved under the brand name Nubeqa™ in more than 80 countries ...
ByBayer AG
MET increases dwell time in the nares promoting delivery via the olfactory route across the blood brain barrier and into the central nervous ...
Currently, enkephalins are limited in their therapeutic potential by their pharmacokinetic profiles due to their inability to cross the blood-brain barrier to reach opioid receptors located in the central nervous system. ...